| | Roger S. Day, ScD
Research Associate Professor, Biostatistics &
Center for Biomedical Informatics Education BA, Wesleyan University, 1972
MA, Wesleyan University, 1981
ScD, Harvard University, 1984
Research Fellowship, National Institute for Environmental Health Sciences, 1986 Research Interests I lead the Educational Resource for Tumor Heterogeneity, and continue the evolution of the Oncology Thinking Cap computer modeling facility, which uses stochastic models of tumor growth to help cancer researchers do thought experiments about cancer biology and treatment, and to help cancer educators develop their abilities to reason across the bridge from basic cancer science through implications for patients and clinical trials. We also develop knowledge management tools to help support a systematic process of model-building and validation. This work is only possible because of the strong contributions and support of a great team. I work with Stan Shackney to understand how disease-free survival curves can be used to shed light on the contentious dosing issues in adjuvant breast cancer treatment. We also work on the genetic evolution of breast cancers, through molecular studies of individual cells in tumor cell samples, and through modeling. Our long-range goal is to radically improve our ability to predict response of individual patients to a variety of cancer therapies and strategies. Together with my student Thomas Richards, I am developing "weakest link" statistical models that reflect more realistically the kinds of relationships that exist in the real world, especially in biology and medicine. We have found examples throughout cancer research of "interactions without main effects", and have developed methods for detecting them that are practical and more effective than the usual linear modeling. (Health Sciences Faculty Research Interests Project) Courses BIOST 2018: Statistical Foundations for Bioinformatics Data Mining
BIOST 2062: Clinical Trials: Methods and Practice
BIOST 2063: Bayesian and Empirical Bayes Statistical Methods
BIOST 2064: Bayesian and Empirical Bayes Computational Methods
MED 5175: Neoplasia and Neoplastic Disease
Statistics of cancer clinical trials; computer-base workshop on clinical trials using OncoTCap V3 Selected Publications "Challenges of Biological Realism and Validation in Simulation-Based Medical Education." Day RS. Artificial Intelligence in Medicine. In press. 2005. "The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer." Day RS, Shackney SE, Peters WP. British Journal of Cancer. Br J Cancer. 2005 Jan 17;92(1):47-54. "Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer." Ramanathan RK, Lee K, Mckolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborn J, Kim H, Day RS, Troetchel M, Finn OJ. Cancer Immunology and Immunotherapy. Epub, September 14, 2004. "Evaluation of the OncoTCap (Oncology Thinking Cap) Simulation in Teaching Medical Students about Clinical Trials: Some Successes and Some Surprises." Day RS, Manning BK, Garrott D, Brufsky AM, Baar J, Egorin MJ, Shirey WE, Friedman C. J Cancer Ed. 19(3):149-155, 2004. "The low over-expression of HER-2/neu in Advanced Colo-Rectal Cancer limits the usefulness of Trastuzumab (Herceptin®) and Irinotecan as therapy. A Phase II trial." Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Cancer Invest. 22(6):858-865, 2004. "Intracellular Patterns of Her-2/neu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Postoperative Clinical Disease Free Survival". Stanley E. Shackney, Charles A. Smith, Agnese Pollice, Kathryn Brown, Roger Day, Thomas Julian, and Jan F. Silverman. Clinical Cancer Research. May 1;10(9):3042-52. 2004. "Phase II Study of Topotecan and Paclitaxel for Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer". Ramalingam S, Belani CP, Day RS, Jacobs SA, Jett JR. Annals of Oncology. Feb;15(2):247-51. 2004. "Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines." Carey Welsh, Roger Day, Claire McGurk, John R. W. Masters, Richard D. Wood and Beate Köberle. Int. J Cancer. Jun 20;110(3):352-61. 2004. "Modeling Cellular Processes with Variational Bayesian Cooperative Vector Quantizer <http://www-smi.stanford.edu/projects/helix/psb04/lu.pdf>". Lu X, Hauskrecht M, Day RS. Proceedings of the Pacific Symposium on Biocomputing. 533-544, January 2004. "Weakest Link Models for Detecting Small Groups of Genes to Predict Lung Cancer Survival, CAMDA'03 (Critical Assessment of Microarray Data Analysis", Richards TJ, Day RS, Kaminski N. Durham, North Carolina, November 2003. "Phase I and Pharmacokinetics study of vinblastine and high dose megestrol acetate." Matin K, Egorin MJ, Bellesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Cancer Chemother Pharmacol. 50(3):179-85, 2002. "Detection of EBV genomes in peripheral blood B cells from solid organ transplant recipients by fluorescent in situ hybridization." Rose C, Green M, Webber S, Kingsley L, Day R, Watkins S, Reyes J, Rowe D. J Clin Microbiol. 40(7):2533-44, 2002. "Integration of a Cancer Research KnowledgeBase with a Cross-Hierarchy Modeling Platform." Day RS, Shirey WE. Proceedings of the 2nd International Conference on Systems Biology, Pasadena, California, Nov 5-7, 2001. "It's harder than we thought it would be: A comparative case study of expert-novice experimentation strategies." Hmelo CE, Nagarajan A, and Day RS. Science Education, in press, 2001. "The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma." Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. Cancer, 91(11):2136-47, 2001. "The Oncology Thinking Cap: Scaffolded use of a simulation to learn clinical trial design." Hmelo CE, Ramakrishnan, Day RS, Shirey WE, Brufsky A, Johnson C, Baar J, Huang,Q. Teaching and Learning in Medicine, 13(3), 2001. "Analysis of therapeutic and immunologic effects of R-24 anti-GD# monoclonal antibody in 37 patients with metastatic melanoma." Kirkwood JM, Mascari RA, Edington HD, Rabkin MS, Day RS, Whiteside TL, Vlock DR, Shipe-Spotloe JM. Cancer, 88(12):2693-2702, 2000. "Detection of bladder cancer using a novel matrix protein, BLCA-4." Konety BR, Nguyen TST, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg RH. Clin Cancer Res. 6, 2618-2625, 2000. "Evidence that anoreceptive intercourse with ejaculate exposure is associated with rapid CD4 cell loss." Wiley DJ, Visscher BR, Grosser S, Hoover DR, Day R, Gange S, Chmiel JS, Mitsuyasu R, Detels R. AIDS, (6) 707-715, 2000. "Effects of high and low prior knowledge on construction of a joint problem space." Hmelo CE, Nagarajan A, and Day RS. Journal of Experimental Education, 69, 36-56, 2000. "Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors." Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH. Journal of Clinical Oncology, 18(18):3288-3294, 2000. "Commentary on Lee & Zelen 'Clinical Trials and Sample Size Considerations: Another Perspective'." Bryant JL, Day RS. Statistical Science, 15:106-108, 2000. "Brain tumor volume measurement: comparison of manual and semiautomated methods." Joe BN, Fukui MB, Meltzer CC, Huang Q, Day RS, Greer PJ, Bozik ME. Radiology, 212(3):811-816, 1999. "Contextualized Questioning to Scaffold Learning From Simulations." Hmelo C and Day R. Computers & Education, 32:151-164, 1999. "Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer." Belani CP, Aisner J, Ramanathan R, Jett J, Greenberger J, Day R, Capazolli MJ, Hiponia D, Engstrom C. Seminars in Radiation Oncology, 7(2):S1-S11-S13-S-14, 1999. "Efficacy of Cisplatin, 5-Fluorouracil, and Paclitaxel Regimen for Carcinoma of the Esophagus." Belani CP, Luketich JD, Landreneau RJ, Kim R, Ramanathan RK, Day R, Ferson PF, Keenan RJ, Posner M, Seger J, Lembersky B. Seminars in Oncology, 1998. "All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes." Adedoyin A, Stiff DD, Smith DC, Romkes M, Bahnson RC, Day R, Hofacker J, Branch RA, Trump DL. Cancer Chemotherapy & Pharmacology, 41:133-139, 1998. "Tumor biology modeling workbench for prospectively evaluating cancer treatments." Day R, Shirey W, Ramakrishnan S, Huang Q. Proceedings of the CESA '98 IMACS Multiconference. April 1998. "Absent or Low Expression of the Zeta Chain in T Cells at the Tumor Site Correlates with Poor Survival in Patients with Oral Carcinoma." Reichert TE, Day RS, Wagner EM, Whiteside TL. Cancer Research, 58(23);5344-5347, 1998. "Tumor Levels of TGF-and EGFR Protein Predict Survival in Patients with Head and Neck Squamous Cell Carcinoma." Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Journal of the National Cancer Institute, 90(11):824-832, 1998. "Lymphatic Mapping with Isoulfan Blue Dye in Head and Neck Squamous Cell Carcinoma." Pitman KT, Johnson JT, Edington H, Barnes EL, Day R, Wagner RL, Myers EN. Archives of Ontolaryngology and Head and Neck Surgery, 124(7):790-793, 1998. "A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis." Trump DL. Smith DC. Stiff D. Adedoyin A. Day R. Bahnson RR. Hofacker J. Branch RA. Cancer Chemotherapy & Pharmacology, 39(4):349-56, 1997. "Efficacy of Cisplatin, 5-Fluorouracil, and Paclitaxel Regimen for Carcinoma of the Esophagus." Belani CP, Luketich JD, Landreneau RJ, Kim R, Ramanathan RK, Day R, Ferson PF, Keenan RJ, Posner M, Seger J, Lembersky B.Seminars in Oncology, 24(6):S19-89-S19-92, 1997. "Adapting Bivariate Frailty Models for Prediction with Application to Biological Markers as Prognostic Factors." Day R, Bryant J, Lefkopoulou M. Biometrika, 84:1, pp. 45-56, 1997. "On the Rate of Convergence of the ECME for Multiple Regression Models with t-distributed Errors." Kowalski J, Tu XM, Day R, Mendoza-Blanco JR. Biometrika, 84(2):269-281, 1997. "Vitamin D Inhibition of Prostate Adenocarcinoma Growth and Metastasis in the Dunning Rat Prostate Model System." Getzenberg RH, Light BW, Lapco PI, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Urology, 50(6):999-1006, 1997. "Using multiple decrement models to estimate risk and morbidity from specific AIDS illnesses. Multicenter AIDS Cohort Study (MACS)." Hoover DR. Peng Y. Saah AJ. Detels RR. Day RS. Phair JP. Statistics in Medicine, 15(21-22):2307-21; discussion 2337-40, 1996. "Chemotherapy in Non-Small Cell Lung Cancer: Pacitaxel/Carboplatin/Radiotherapy in Regionally Avanced Diseases." Belani CP, Aisner J, Bahri S, Jett J, Day R, Capazolli MJ, Hiponia D, Engstrom C. Seminars in Oncology, 23(6 Suppl 16):113-116, 1996. "The role of immunological effector-cells in the development of posttransplant lymphoproliferative disorders (PTLD)." Shpilberg O, Wilson J, Green M, Nalesnik M, Day R, Herberman RB, Whiteside T. Blood, 86(10)[1]:1354, 1995. "Incorporating toxicity considerations into the design of two-stage phase II clinical trials." Bryant J, Day R. Biometrics, 51:1372-1383, 1995. "An application of decision theory to patient screening for an autologous tumor vaccine trial." Shannon WD, Bryant J, Logan TF, Day R. Statistics in Medicine, 14:2099-2110, 1995. "Phase II trial of oral 1,25-dihydroxyvitamin d (calcitriol) in hormone refractory prostate cancer." Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Urologic Oncology, 1:195-198, 1995. "Treatment of heaptic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial." Rubin JT, Lotze MT, Rosenfelder D, Brumfield A, Howells R, Schwartz R, Sylvestri S, Sammon J, Bron K, Orens P, Zajko A, Swanson D, Day R. Annals of Surgical Oncology, 2:351-359, 1995. "Calculation of lytic units for the expression of cell mediated cytotoxicities." Bryant J, Day R, Whiteside T, Herberman R. J Immuno Methods, 146:91-103, 1992. "The selective use of amsa following high-dose cytarabine in patients with acute myeloid leukaemia in relapse." Larson RA, Day RS, Axarnia N, Bennett JM, Browman G, Goldberg J, Gottlieb A, Grunwald H, Miller K, Raza A, Vogler R, Winto E, Preisler H. Brit J Hema., 82:337-346, 1992. "Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial." Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside TL, Titus-Ernstoff L, Kirkwood JM. Cancer Research, 52:91-103, 1992. "Cold ischemia time versus outcome of human liver transplantation using UW solution." Furukawa H, Todo S, Imventarza O, Wu M, Day R, and Starzl TE. Transplant Proc., 23:1550-1551, 1991. "Preliminary Trial of Nonrecombinant Interferon Alpha in Recurrent Squamous Cell Carcinoma of the Head and Neck." Vlock DR, Johnson J, Myers E, Day R, Gooding WE, Whiteside T, Pelch K, Sigler B, Wagner R, Colao D, et al. Head and Neck, 13(1):15-21, 1991. "Empirical Bayes analysis for systems of mixed models with linked autocorrelated random effects." Bryant J, Day R. Amer Stat Assoc., 86:1007-1012, 1991. "Gene Amplification and gene dosage in cell lines derived from squamous cell carcinoma of the head and neck." Yin X, Donovan-Peluso M, Whiteside T, Johnson J, Day R, Herberman R, Locker J.Genes, Chromosomes & Cancer,3:443-454, 1991. "Natural killer (NK) cytotoxicity in diagnosis of immune dysfunction: criteria for a reproducible assay." Whiteside T, Bryant J, Day R, Herberman R. Journal of Clinical Laboratory Analysis, 4:102-114, 1990. "Evaluation of tetrazolium-based semi-automatic colorimetric assay for measurement of antitumor cytotoxicity." Heo DS, Park J-G, Hata K, Day R, Herberman R, Whiteside T. Cancer Research, 50:3681-3690, 1990. "Direct relationship between Remission duration in acute myeloid leukemia and cell cycle kinetics." Raza A, Preisler H, Day R, Yasin Z, White M, Lykins J, Kukla C, Barcos M, Bennett J, Browman G, Browman G, Goldberg J, Grunwald H, Larson R, Vardiman J, Vogler R. Blood, 76 (11): 2791-7, 1990. "MDR1 transcript levels as an indication of resistant disease in acute nonlymphocytic leukemia." Preisler HD, Gottesman M, Raza A, Pastan I, Day R. Br. J. Haematol, 75:340-345, 1990. "MDR1 Transcript Levels As An Indicator of Resistant Disease in Acute Myelogenous Leukaemia." Sato H, Preisler H, Day R, Raza A, Larson R, Browman G., Goldberg J, Vogler R, Grunwald H, Gottlieb A, et al. British Journal of Haematology, 75(3):340-345, 1990. "A phase IA trial of the combination of recombinant interferons gamma and alpha in patients with metastatic renal cell carcinoma. " Ernstoff M, Gooding W, Nair S, Bahnson R, Miketic L, Banner B, Day R, Titus-Ernstoff J. Clin. Invest., 8(10):1637-49, 1990. "Investigation of a potential cancer cluster in Randolph, Massachusetts." Day R., Ware J., Wartenberg D, Zelen M. Journal of Clinical Epidemiology, 42:137-150, 1988. "A multitype branching model for heterogeneous cell populations." Day R. Math BioSciences, 78:73-80, 1986. "Treatment sequencing, asymmetry, and uncertainty: new strategies for combining cancer treatments." Day R. Cancer Res, 46:3886-3887, 1986. "Chemotherapy for metastatic non-small cell bronchogenic carcinoma: Cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, Generation IV)." Ruckdeschel JC, Day R, Weissman CH, Stolback LL, Creech RH. Canc TR Rep., 68:1325-1329, 1984. "Improved echocardiographic visualization in emphysematous subjects." Cohen J, Anwar KN, Day R. J Med Soc NJ, 90:815-181, 1983. "A randomized phase II study of meta-AMSA and neocarzinostatin in non-small bronchogenic carcinoma." Ettinger DS, Day R, Ferrard JA, Ruckdeschel JC, Woll JE, Creech RH, Vogl SE. Am J Clin Onc., 167-170, 1983. Contact Information Sterling Plaza
201 North Craig Street, Suite 325
Pittsburgh, PA 15213
Telephone: 412-383-1573
Facsimile: 412-383-1535
Email: day@upci.pitt.edu |  |
